Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT.
One of the mechanisms by which platelet-derived microparticles elicit procoagulant activity is by an increased exposure of phosphatidylserine on their surface. We have previously demonstrated the utility of an activated factor X-based assay for the detection of procoagulant phospholipid activity [Xa clotting time (XACT)]. The objective of this study was to further characterize the specificity of the XACT to detect microparticle-associated procoagulant phospholipid activity. XACT testing for procoagulant phospholipid was measured using an ST4 machine and microparticle counting was performed using flow cytometry for Annexin V binding. Plasma microparticle counts were significantly correlated to XACT times (P = 0.0001). The XACT assay was insensitive to tissue factor, whereas the addition of microparticles to a whole blood sample shortened XACT times. Procoagulant phospholipid activity could be detected in both citrate and EDTA anticoagulated samples; however, XACT times and microparticle counts were more stable in EDTA anticoagulated samples over a 60 min period. The procoagulant phospholipid activity of microparticles generated by collagen stimulation was significantly impaired in EDTA anticoagulated samples when compared with citrate. Microparticles were capable of higher degrees of thrombin generation than equivalent concentrations of phosphatidylserine (as assessed by XACT times), suggesting that other factors bound to the microparticle surface enhance the procoagulant response. In conclusion, the XACT assay is a specific method for the detection of procoagulant phospholipid activity arising from phosphatidylserine on the microparticle surface; however, other factors presumably bound to the surface of the microparticle may also contribute to enhanced thrombin generation detectable by prothrombinase assays.
Connor
David E
DE
Department of Haematology and Haematological Stem Cell Transplantation, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia. dconnor@stvincents.com.au
Exner
Thomas
T
Ma
David D F
DD
Joseph
Joanne E
JE
D017304:Annexin A5 / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests / Q000379:methods* / Q000592:standards; D055252:Cell-Derived Microparticles / Q000737:chemistry*; D019343:Citric Acid / Q000494:pharmacology; D003094:Collagen / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D010718:Phosphatidylserines / Q000502:physiology*; D012680:Sensitivity and Specificity; D013917:Thrombin / Q000096:biosynthesis
D017304:Annexin A5; D010718:Phosphatidylserines; D019343:Citric Acid; D003094:Collagen; D004492:Edetic Acid; D013917:Thrombin